Parchem is a qualified supplier of Chloroquine Phosphate to the Pharmaceutical Industry!

by Jacob Klein
Publish: March 31 2020 | Updated: March 31 2020
article_image

At Parchem – fine & specialty chemicals, we strive to always be ahead in chemical innovations, having established partnerships with manufacturers across the globe, in order to best serve our customers in the pharmaceuticals industry.  We are excited to feature chloroquine phosphate among our supply. 

Chloroquine phosphate has a CAS number 54-05-7. This 4-aminoquinoline compound classified as an active pharmaceutical ingredient (API.) Chloroquine phosphate is a well-known antimalarial and amebicide, given orally. It has been administered in the treatment of rheumatoid arthritis and other chronic conditions; however, there are also numerous documented side-effects and contraindications. Warnings about under-qualified companies and
even individuals procuring chloroquine phosphate for treatment of COVID-19 have recently risen along with increased awareness of the drug.

At Parchem, customer qualification is integral to our sourcing process. Our experienced team ONLY supplies the correct grade (USP or food grade) of any raw material to proven pharmaceutical companies who with established drug research & development track records. Our staff will help source the exact chemical you need based on your demonstrated end-use and grade specification, in strict accordance with federal and international regulatory agency standards. Our commitment to personal and environmental safety is demonstrated by our longstanding ISO:9001 certification, membership with the professional associations DCAT, NACD and SOCMA. We are FDA, DEA and TTB compliant.

Contact Parchem today and make us your chemical sourcing specialists!

Click here for a quote on chloroquine phosphate!

Related news
related_article_image
related_article_image
Cumene Hydroperoxide: A unique organic peroxide with polymerization inhibitor properties
Read full story
Parchem supplies Dibasic Esters 09-05-2014
Read full story
related_article_image
related_article_image